<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1458">
  <stage>Registered</stage>
  <submitdate>1/02/2007</submitdate>
  <approvaldate>1/02/2007</approvaldate>
  <nctid>NCT00430547</nctid>
  <trial_identification>
    <studytitle>Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies</studytitle>
    <scientifictitle>Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>03/53</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Graves' Ophthalmopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Carbimazole, radio-active iodine (I131)

Treatment: drugs: Carbimazole, radio-active iodine (I131)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Onset or progression of ophthalmopathy following radio-active iodine therapy</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Graves' disease diagnosed in the last 3 months, regardless of the presence of
             ophthalmopathy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant
             loss of vision

          -  Age &lt; 18 years

          -  Inability to consent to participation in the study

          -  Pregnancy

          -  History of radio-active iodine therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Barwon Health - The Geelong Hospital - Geelong</hospital>
    <postcode>3220 - Geelong</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Barwon Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Melbourne</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether radioactive iodine, as compared to
      anti-thyroid medications, is a risk factor for the development or progression of
      thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease.
      The other aim of this study is to determine the incidence of the various ophthalmopathy
      subtypes and the utility of orbital antibodies in the diagnosis, classification and
      monitoring of patients with thyroid-associated ophthalmopathy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00430547</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jack R Wall, BMBS, FRACP, PhD</name>
      <address>University of Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>